Skip to Main content Skip to Navigation
New interface
Journal articles

Development of metronidazole-resistant lines of Blastocystis sp.

Abstract : Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTRR) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTRR lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTRR lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTRR lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.
Document type :
Journal articles
Complete list of metadata
Contributor : Didier Gigmes Connect in order to contact the contributor
Submitted on : Tuesday, February 7, 2017 - 4:35:31 PM
Last modification on : Thursday, November 4, 2021 - 3:24:27 AM

Links full text




L. A. Dunn, K. S. W. Tan, P. Vanelle, T. Juspin, M. D. Crozet, et al.. Development of metronidazole-resistant lines of Blastocystis sp.. Parasitology Research, 2012, 111 (1), pp.441--450. ⟨10.1007/s00436-012-2860-7⟩. ⟨hal-01460365⟩



Record views